Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (1287)	1/11/1999 4:33:00 AM
From: Anthony Wong	Respond to of 1722

SmithKline Bartering for Cuban Meningitis Vaccine, Times Says Bloomberg News January 10, 1999, 7:00 p.m. ET London, Jan. 11 (Bloomberg) -- SmithKline Beecham Plc, Europe's No. 3 drugmaker, is resorting to the barter system to secure rights to a meningitis vaccine developed in Cuba, the Times of London reported without citing sources. To address U.S. concerns about trade with the island nation, the company has provisionally agreed payments to its Finlay Institute will be in goods such as medicine and food while the drug moves through the development process, the newspaper said. Negotiations with the institute have been made more difficult as a result of the Helms- Burton Act, a U.S. law which prohibits trade with Cuba, the newspaper said. Drugmakers such as Merck & Co. and Monsanto Co., hoping to bring blockbuster drugs to market in 1999, will face tougher restrictions from health insurers that could slow sales and hurt profits. (Times 1/11 48 www.the-times.co.uk) --Ben Richardson in the London newsroom (44 171) 330 7027/mpk